Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Woodford, Malin put $50m into Kymab

This article was originally published in Scrip

Executive Summary

Cambridge, UK-based Kymab has raised $50m to complete a total $90m series B financing round which will allow the firm to further its drug discovery platform, Kymouse. Kymab, founded in 2009, has now raised a total of $120m in equity financing. The $50m is being invested by Woodford Patient Capital Trust and Malin. It follows on from $40m invested by the Wellcome Trust and the Bill and Melinda Gates Foundation earlier in the series B round.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel